Otsuka Pharmaceutical has signed an agreement to acquire all assets related to Cantargia's early-clinical stage CAN10 ...

Relevant biomarkers include cytokines and targets such as IL-4, IgE, IL-5, IL-13, IL-33, and TSLP (Figure 2). A number of ...

After IL-1 binds to the type I receptor, it will couple with the IL-1 accessory protein and form a heterodimer that leads to transmembrane signaling (Figure 13-1).

IL-1 is considered one of the key mediators involved in the pathogenesis of OA, causing inflammation, joint pain, and ...

Protagonist Therapeutics Inc. (NASDAQ:PTGX) is one of the best mid cap pharma stocks to buy. On July 21, Protagonist Therapeutics announced that Johnson & Johnson (NYSE:JNJ) submitted a New Drug ...

Icotrokinra was jointly discovered and is being developed pursuant to the license and collaboration agreement between ...

Icotrokinra is a first-in-class targeted oral peptide that blocks interleukin (IL) 23 and its receptor, which plays a key ...

Iinterleukin-1 (IL-1) is a proinflammatory cytokine with various immune, degradative, and growth promoting roles.There are two IL-1 agonistic proteins — IL-1β and IL-1α — and one antagonistic protein, ...